Arun Tailor

Arun Tailor

Auto-generated profile, based on publicly available information

Arun Tailor

MRC Center for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool , Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
SKSeung-Hyun Kim
Seung-Hyun Kim
KSKaty Saide
Katy Saide
JFJohn Farrell
John Farrell
LFLee Faulkner
Lee Faulkner
ATArun Tailor
Arun Tailor
DNDean J. Naisbitt
Dean J. Naisbitt
Drug‐induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug‐responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin‐clavulanate. Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon‐gamma (IFN‐γ) when cultured with amoxicillin and/or clavulanic acid. Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4+ and CD8+ T‐cell clones expressing CCR, chemokine (C‐C motif) receptor 4, CCR9, and chemokine (C‐X‐C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross‐reactivity was observed between the two drug antigens. Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN‐γ, interleukin‐22 and cytolytic molecules. In contrast, cytokine secretion by the clavulanic acid clones was more restricted. CD4+ and CD8+ clones were major histocompatability complex class II and I restricted, respectively, with the drug antigen being presented to CD4+ clones in the context of HLA‐DR molecules. Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen‐presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4‐16 hours activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release. Conclusion: Both amoxicillin‐ and clavulanic acid–specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin‐clavulanate. (Hepatology 2015;62:887‐899)

21 September 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
XMXiaoli Meng
Xiaoli Meng
CECaroline J. Earnshaw
Caroline J. Earnshaw
ATArun Tailor
Arun Tailor
RJRosalind E. Jenkins
Rosalind E. Jenkins
JWJames Waddington
James Waddington
BPB. Kevin Park
B. Kevin Park

3 January 2025 in The EMBO Journal
Verified
Journal Article
Open access
HEHala Estephan
Hala Estephan
ATArun Tailor
Arun Tailor
RPRobert Parker
Robert Parker
MKMcKenzie Kreamer
McKenzie Kreamer
IPIoanna Papandreou
Ioanna Papandreou
AGAmato J Giaccia
Amato J Giaccia
Hypoxia is a common feature of solid tumors that has previously been linked to resistance to radiotherapy and chemotherapy, and more recently to immunotherapy. In particular, hypoxic tumors exclude T cells and inhibit their activity, suggesting that tumor cells acquire a mechanism to evade T-cell recognition and killing. Our analysis of hypoxic tumors indicates that hypoxia downregulates the expression of MHC class I and its bound peptides (i.e., the immunopeptidome). Hypoxia decreases MHC-I expression in an oxygen-dependent manner, via activation of autophagy through the PERK arm of the unfolded protein response. Using an immunopeptidomics-based LC-MS approach, we find a significant reduction of presented antigens under hypoxia. Inhibition of autophagy under hypoxia enhances antigen presentation. In experimental tumors, reducing mitochondrial metabolism through a respiratory complex-I inhibitor increases tumor oxygenation, as well as MHC-I levels and the immunopeptidome. These data explain the molecular basis of tumor immune evasion in hypoxic conditions, and have implications for future therapeutic interventions targeting hypoxia-induced alterations in antigen presentation.

30 September 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
ATArun Tailor
Arun Tailor
JWJames Waddington
James Waddington
XMXiaoli Meng
Xiaoli Meng
BPB. Kevin Park
B. Kevin Park

31 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XMXiaoli Meng
Xiaoli Meng
JWJames Waddington
James Waddington
ATArun Tailor
Arun Tailor
ALAdam Lister
Adam Lister
JHJane Hamlett
Jane Hamlett
MSMichael B. Sporn
Michael B. Sporn

16 September 2016 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
LFLee Faulkner
Lee Faulkner
AGAndrew Gibson
Andrew Gibson
ASAndrew Sullivan
Andrew Sullivan
ATArun Tailor
Arun Tailor
TUToru Usui
Toru Usui
BPB. Kevin Park
B. Kevin Park
A number of serious adverse drug reactions are caused by T-cells. An association with HLA alleles has been identified with certain reactions, which makes it difficult to develop standardized preclinical tests to predict chemical liability. We have recently developed a T cell priming assay using the drug metabolite nitroso sulfamethoxazole (SMX-NO). We now report on reproducibility of the assay, establishment of a biobank of PBMC from 1000 HLA-typed volunteers, and generation of antigen-specific responses to a panel of compounds. Forty T cell priming assays were performed with SMX-NO; 5 gave weak responses (1.5-1.9) and 34 showed good (SI 2.0-3.9) or strong responses (SI >4.0) using readouts for proliferation and cytokine release. Thus, SMX-NO can be used as a model reagent for in vitro T-cell activation. Good to strong responses were also generated to haptenic compounds (amoxicillin, piperacillin and Bandrowski’s base) that are not associated with an HLA risk allele. Furthermore, responses were detected to carbamazepine (in HLA-B*15:02 donors), flucloxacillin (in one HLA-B*57:01 donor) and oxypurinol (in HLA-B*58:01 donors), which are associated with HLA-class I-restricted forms of hypersensitivity. In contrast, naïve T cell priming to ximelagatran, lumiracoxib and lapatinib (HLA-class II-restricted forms of hypersensitivity) yielded negative results. Abacavir, which activates memory T-cells in patients, did not activate naïve T-cells from HLA-B*57:01 donors. This work shows that the priming assay can be used to assess primary T-cell responses to drugs and to study mechanisms T-cell priming for drugs that display HLA class I restriction. Additional studies are required to investigate HLA-class II-restricted reactions.